DARA Biosciences Inc

DARA Biosciences — IPO Roadshow (May 2008)

34 slides from DARA Biosciences's IPO roadshow presentation, May 19, 2008

  1. Slide 1: Investor Presentation 2Q08

    Filed Pursuant to Rule 433 Registration No. 333-150150 May 19, 2008 Investor Presentation 2Q08 1

  2. Slide 2: Registration Statement; SEC Filings

    Registration Statement; SEC Filings The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with

  3. Slide 3: Forward-Looking Statements

    Forward-Looking Statements CERTAIN STATEMENTS IN THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO STATEMENTS, ESTIMATES, ASSUMPTIONS AND PROJECTIONS OF FUTURE TRENDS AND OF OUR ANTICIPATED FUTURE PERFORMANCE, CONSTITUTE “FORWARD-LOOKING STATEMENTS.” SUCH FORWARD LOOKING STATEMENTS INVOLVE KNOWN AND UNKNO

  4. Slide 4: History

    History Founded by Steve Gorlin in 2002 Funded with $24 million in private equity from three financing rounds between 2003-2006 Completed reverse-merger with Point Therapeutics on 2/12/08 and now trades as DARA BioSciences (NasdaqCM: DARA) $30 million shelf went effective on 4/18/08 with no review 4

  5. Slide 5: The Company

    The Company Five drug development programs targeting multi- billion dollar market opportunities Product focused with strong patent protection Highly efficient and flexible development capabilities Working in lowest cost, highest return stages of drug development In-house core of senior development s

  6. Slide 6: Thomas W. D'Alonzo, John Didsbury, Steve Gorlin

    Nationally featured in renowned publications, such as The Wall Street Journal and Fortune Magazine, as an authority in the healthcare industry Founder and Co- Founder of several highly successful biotechnology and pharmaceutical companies Steve Gorlin Chairman of the Board including Medicis Pharmace

  7. Slide 7: Board Directors

    Chairman, Tranzyme, Inc. and Tranzyme Pharma Inc. Director, MethylGene Inc. (TSX:MYG) Former VP, Clinical Development; Daiichi Pharmaceutical Corporation David J. Drutz, M.D. Board Director Former VP, Biological Sciences and VP, Clinical Investigation, Smith Kline & French Laboratories Former Presid

  8. Slide 8: Corporate Strategy

    Corporate Strategy Produce a revenue stream derived from the licensing and/or sale of drug candidates to large pharmaceutical companies Acquisition, Development and Sale Drug Marketing Discovery Approval Discovery Pre-Clinical IND Phase I Phase II Phase III Research DARA HIGHEST FOCUS HIGHEST RISK $

  9. Slide 9: Grim Pipeline Prognosis for Pharmaceutical Industry

    Grim Pipeline Prognosis for Pharmaceutical Industry More Is Less* New drug approvals by the FDA are on the decline as pharmaceutical companies spend more on R&D Conventional 60 $45 New Small Molecule Drug Approvals(right axis) pharmaceutical R&D Spending (left axis) development model is $30 40 not p

  10. Slide 10: Earlier Phase Deals Yielding Higher Value Terms

    Earlier Phase Deals Yielding Higher Value Terms Change in Cost of Deal Terms 2003 by Clinical Phase of Asset* 2006 400 Value of Phase I 350 365 and II development 300 250 280 300 deals have 200 increased by 75% 190 171 150 160 100 50 0 Phase I Phase II Phase III *SOURCE: Jones, A. Minimizing Leakage

  11. Slide 11: Pipeline Portfolio Strategy

    Pipeline Portfolio Strategy Maintain a rolling pipeline of 4-6 drug programs Constant scanning for new drug program acquisitions Cut programs quickly as adverse results occur to focus resources on greater value opportunities Balanced risk approach to pipeline creation with multiple drug development

  12. Slide 12: Current Pipeline

    Current Pipeline Compound/ Indication(s) Mechanism Stage Source Program of Action KRN5500 Neuropathic Pain Inhibits EPSPs Phase II Kirin/MGH Preclinical DB959 Type 2 Diabetes PPAR Agonist Bayer IND 4Q08 Preclinical DB160 Type 2 Diabetes DPP-IV Inhibitor Nuada IND 1Q09 Type 2 Diabetes PPAR Agonist Pr

  13. Slide 13: Neuropathic Pain: KRN5500

    Neuropathic Pain: KRN5500 Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Active component of KRN5500 has been shown to inhibit nerve cell pain signals Inhibits EPSPs similar to a -opioid agonist and Neurontin Unsatisfied market – no effective the

  14. Slide 14: CIPN: An Unexploited Market Opportunity for KRN5500

    CIPN: An Unexploited Market Opportunity for KRN5500 Inadequate current therapies No marketed medicines are approved for use in treating CIPN Variable and minimal benefits with gabapentin, opioids, tricyclic anti-depressants and anti-convulsants Low potential competition Cesamet (synthetic cannabinoi

  15. Slide 15: KRN5500 Phase 2 Trials

    KRN5500 Phase 2 Trials Current Phase 2a trial: Assess the safety and alleviation of neuropathic pain in terminally- ill cancer patients Randomized, double-blind, placebo controlled study in 18 patients over 14-week duration Study completion expected in 4Q08 Next Phase 2 trial: Commence open label st

  16. Slide 16: Type 2 Diabetes: DB959 (PPAR Agonist)

    Type 2 Diabetes: DB959 (PPAR Agonist) (delta/gamma) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Activates genes involved in metabolism of sugars and fats, improving the body’s ability to regulate blood sugar Raises good HDL cholesterol and low

  17. Slide 17: Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia

    Non-Clinical Studies Suggest Greater Cardiac Safety than Avandia ® Avandia ® Dose Cardiac Effect @ 3 times human exposure* @ 42 times human exposure* Avandia: Toxicology study on 8 dogs (4M and 4F), results on day 24 * Based on AUC of 3 mg*h/l at 8mg/day dose DB959 Dose Cardiac Effect @ 19 times hum

  18. Slide 18: DB959 is not like Avandia and Actos

    DB959 is not like Avandia ® and Actos ® Different structure - different activities (DB959 is not a TZD) Avandia® Actos® Structure not shown - confidential DB959 Treating diabetes in ways that Avandia® and Actos® potentially can’t (correcting altered blood lipids CV Disease) 18

  19. Slide 19: DB959 Non-Clinical Activity

    DB959 Non-Clinical Activity Potentially leading successor to Avandia ® and Actos® (whose combined 2006 sales were > $5.6 billion). The Company believes the following based on non-clinical data: Glucose control equal to or better than Avandia Lowers Triglycerides better than Avandia Increases good HD

  20. Slide 20: PPAR Agonist: Early Lucrative Exits

    PPAR Agonist: Early Lucrative Exits Drug Stage Drug Companies Deal Size Date PPAR $372MM + Pre-Clinical Agonist Plexxikon / Wyeth 10/28/04 Royalties (PLX-104) Phase 1 & PPAR $508MM + Metabolex / JNJ 6/26/06 Phase 2 Modulators Royalties 20

  21. Slide 21: Type 2 Diabetes: DB160 (DPP-IV Inhibitor)

    Type 2 Diabetes: DB160 (DPP-IV Inhibitor) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Di-peptidyl peptidase-IV (DPP-IV) is an enzyme that inactivates a key hormone involved in promoting control of blood sugar levels Inactivation of DPP-IV thus

  22. Slide 22: DB160 Activity

    DB160 Activity Inhibition of DPP-IV Activity in Dogs with a Single Dose Desired DPP-IV target product profile: 1. Taken orally, once a day 2. Inhibiting DPP-IV for optimal blood sugar control 3. >70% inhibition through 12 hours at 10 mg/kg 4. Maximize safety potential by minimizing inhibition overni

  23. Slide 23: DPP-IV Inhibitor: Early Lucrative Exits

    DPP-IV Inhibitor: Early Lucrative Exits Drug Stage Drug Companies Deal Size Date Phase 1b DPP-IV Inhibitor $300MM Alantos / Amgen 6/07/07 (Completed) ALS-2-0426 Acquisition DPP-IV Inhibitor $304MM + Phase 2 Glenmark / Merck KgaA 10/17/06 GRC-8200 Royalties 23

  24. Slide 24: Type 2 Diabetes: DB900 (PPAR Agonists)

    Type 2 Diabetes: DB900 (PPAR / / Agonists) (gamma/alpha/delta) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Activates genes involved in metabolism of sugars and fats, improving the body’s ability to regulate blood sugar Raises good HDL choleste

  25. Slide 25: DB900 (PPAR Agonists)

    DB900 (PPAR / / Agonists) Strong follow-up molecules to DB959 Potentially safer than Avandia ® and Actos ® Potential to have greater efficacy than DB959 on dyslipidemia in diabetics (>TG , HDL , LDL ) Potential to deliver weight loss Potential utility in other diseases (e.g. psoriasis, Alzheimer’s d

  26. Slide 26: DB959 and DB900 vs. Avandia and Actos

    DB959 and DB900 vs. Avandia and Actos DB959 DB900 Avandia Actos Glucose Control Increase HDL Lower Triglycerides Lower LDL Lower Total Cholesterol Weight Control 26

  27. Slide 27: Psoriasis: DB200 (Topical)

    Psoriasis: DB200 (Topical) Candidate Selection Lead Proof of Pre-Clinical Identification Principle Development Phase 1 Phase 2a Potentially inhibits the proliferation of skin cells by cutting off their energy source - resulting in less flaking of the skin and restoration of normal skin tone Potentia

  28. Slide 28: The Promise of DB200 for Psoriasis

    The Promise of DB200 for Psoriasis No other drug in its class for the treatment of psoriasis New topical therapies in development mainly address inflammation (e.g. PMX-53, PTH1-34, AN-2728) DB200 reduces both inflammation and skin cell growth Potentially a once a day topical therapy (>76% of treated

  29. Slide 29: Current Pipeline

    Current Pipeline Candidate Selection Lead Proof of Pre-Clinical Indication Drug Identification Principle Development Phase 1 Phase 2a Neuropathic Pain KRN5500 First in Class – No Competition for Drugs of its Type Type 2 Diabetes DB959 Leader in its Class – No Competition in the Clinic Type 2 Diabete

  30. Slide 30: Projected Future Key Milestones

    Projected Future Key Milestones IND IND IND Phase 1 Submission Submission Submission Completion DB959 DB160 DB900 DB959 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 KRN5500 Second Phase 2a Trial KRN5500 KRN5500 complete Second Initial Phase 2a Trial Phase 2a Trial IND Phase 1 initiation complete Submission Complet

  31. Slide 31: Financial Snapshot at 3/31/08

    Financial Snapshot at 3/31/08 Cash $6.8 million 1Q08 Net Loss ($2.4) million Shares Outstanding 27.2 million Options & Warrants Outstanding 3.5 million Insider Ownership 16.0% Share Price Range (30-Day)* $2.10-$3.20 Market Capitalization** $64 million *Range of closing prices from 4/1/08 – 4/30/08 *

  32. Slide 32: DARA – Potential for Value Creation

    DARA – Potential for Value Creation Key Assets: 5 therapeutic compounds with strong IP addressing large markets Surgi-Vision: Privately held company targeting Deep Brain Stimulation (DBS), with a strategic relationship with Advanced Bionics, a subsidiary of Boston Scientific. DARA owns 9.7%. MiMedX

  33. Slide 33: Summary

    Summary Clearly defined business strategy addressing large pharma pipeline gaps Diverse portfolio of programs targeting multi-billion dollar market segments Limited reliance on a single drug candidate or therapeutic category Pursuing both proven and innovative mechanisms Lower risk / lower cost appr

  34. Slide 34: Investor Presentation 2Q08

    Investor Presentation 2Q08 34

DARA BioSciences — IPO Roadshow (May 2008) on 6ix